Prime Minister Justin Trudeau has announced an agreement with Novavax to produce a vaccine against COVID-19 in Canada. In the new Montreal facility, the Federal Government signs a “memorandum of understanding” with the company to produce vaccines. A new biomanufacturing facility for the National Research Council is not scheduled to be completed until July. It could be months before a prospective vaccine candidate is approved in Canada, let alone shipped to delivery sites. “tens of millions” of doses, Trudeau says, will be made domestically if the vaccine is considered safe and effective.
Questions about the lack of domestic production capacity for COVIid-19 vaccines have been raised by the federal government. Late last week, Novavax submitted its vaccine candidate to Health Canada for approval. The outbreak of a new coronavirus variant, known as COVIID-19, is being investigated by the Canadian Ministry of Health and the number of cases in Canada has risen to 745, with 14 deaths so far this year. The number of cases confirmed is 745; 14 people died.
A new deal was announced by Prime Minister Justin Trudeau with two European vaccine manufacturers. The move will enable Canada to become more self-dependent on the production of vaccines. By the end of September, the federal government hopes to have all Canadians vaccinated. The government is also making investments in researching COVID-19 therapeutics with Canadian bio producers.